RxDoctor Payments Data

Teri Meadows

Nurse Practitioner · Meridian, IDNPI 1457846206

Payments from drug & device makers

$1,018in general payments, 2019–2025

Across 15 payments — averaging $67.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$265
  • AstraZeneca$234
  • Radius Health, Inc.$122
  • UCB, Inc.$120
  • Johnson & Johnson$112
  • Novartis$64
  • plus $101 from 2 others

What the payments were for

  • Food & beverage$91990%
  • Education$9910%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,018 in reported general payments places this provider in the 75th percentile of 570 nurse practitioner providers in Idaho.

See all nurse practitioner providers in Idaho

Medicare billing

Part B allowed, 2024
$37,022
Medicare patients
183
Services billed
505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib109$695,968
Skyrizi PenRisankizumab-Rzaa29$560,901
Xeljanz XrTofacitinib Citrate75$548,567
Humira(Cf) PenAdalimumab44$361,480
Cosentyx Sensoready (2 Pens)Secukinumab37$319,689
Taltz AutoinjectorIxekizumab44$296,249
XeljanzTofacitinib Citrate41$199,378
OtezlaApremilast43$184,972
Cimzia (2 Pack)Certolizumab Pegol29$171,526
OrenciaAbatacept27$154,991
Orencia ClickjectAbatacept27$145,025
Enbrel SureclickEtanercept13$93,493
KevzaraSarilumab20$84,919
SimponiGolimumab14$80,859
BenlystaBelimumab13$60,990

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$265$695,968109 claims
AmgenOtezla$51$184,97243 claims
UCB, Inc.Cimzia (2 Pack)$120$171,52629 claims
Johnson & JohnsonSimponi$112$80,85914 claims
Radius Health, Inc.Tymlos$122$50,29619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 570 nurse practitioner providers in Idaho.

Other nurse practitioner in Meridian

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →